Members |
targetComponentId |
Gluteal muscle (& short hip rotator) |
Internal rotator of hip joint |
Gluteal muscle (& short hip rotator) |
Muscle of buttock |
Gluteal syndrome |
Myofascial pain |
Gluteal syndrome |
Piriformis syndrome |
Gluten free diet |
Wheat-free diet |
Gluten free diet |
Gluten free diet |
Gluten sensitivity |
Gluten intolerance |
Gluten sensitivity |
Celiac disease (disorder) |
Gluten-free/wheat-free baguette |
Gluten-free/wheat-free baguette (product) |
Gluten-free/wheat-free digestive biscuits |
Gluten-free and wheat-free digestive biscuits (product) |
Glyburide 1.5mg |
Glibenclamide micronised 1.5 mg oral tablet |
Glycerol - chemical |
Glycerol |
Glycerol product |
Product containing glycerol (medicinal product) |
Glycerol/glycol/macrogol adverse reaction |
Adverse reaction to macrogol |
Glycerol/glycol/macrogol adverse reaction |
Glycerol adverse reaction |
Glycerol/glycol/macrogol adverse reaction |
Adverse reaction to glycol (disorder) |
Glycerol/glycol/macrogol allergy |
Allergy to glycerin |
Glyceryl trinitrate 10mg/24hours transdermal patch |
Product containing precisely glyceryl trinitrate 416.667 microgram/1 hour prolonged-release transdermal patch (clinical drug) |
Glyceryl trinitrate 15mg/24hours transdermal patch |
Glyceryl trinitrate 625 microgram/hour prolonged-release transdermal patch |
Glyceryl trinitrate 1mg/mL injection solution 10mL ampule |
Glyceryl trinitrate 1 mg/mL solution for injection |
Glyceryl trinitrate 1mg/mL injection solution 50mL vial |
Glyceryl trinitrate 1 mg/mL solution for injection |
Glyceryl trinitrate 1mg/mL injection solution 5mL ampule |
Glyceryl trinitrate 1 mg/mL solution for injection |
Glyceryl trinitrate 25mg/5mL injection |
Product containing precisely glyceryl trinitrate 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Glyceryl trinitrate 400micrograms CFC-free spray |
Glyceryl trinitrate 400 microgram/actuation sublingual spray |
Glyceryl trinitrate 50mg/10mL injection |
Product containing precisely glyceryl trinitrate 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Glyceryl trinitrate 50mg/10mL solution for injection ampule |
Product containing precisely glyceryl trinitrate 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Glyceryl trinitrate 5mg/24hours transdermal patch |
Glyceryl trinitrate 208.333 microgram/hour prolonged-release transdermal patch |
Glyceryl trinitrate 5mg/mL injection solution 5mL ampule |
Product containing precisely glyceryl trinitrate 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Glycocholic acid, conjugated |
Glycocholic acid |
Glycogen phosphorylase kinase deficiency, X-linked |
Glycogen storage disease type IX (disorder) |
Glycogen phosphorylase kinase deficiency, X-linked |
Glycogen storage disease due to muscle phosphorylase kinase (PhK) deficiency is a benign inborn error of glycogen metabolism characterized by exercise intolerance. |
Glycolic acid |
Glycolate |
Glycolic acid |
Glycolic acid |
Glycopyrrolate 200micrograms/1mL injection |
Glycopyrronium bromide 200 microgram/mL solution for injection |
Glycopyrrolate 600micrograms/3mL injection |
Glycopyrronium bromide 200 microgram/mL solution for injection |
Glycosylated hemoglobin A |
Glycated hemoglobin-A1c (substance) |
Glycosylated hemoglobin-c fraction |
Glycated hemoglobin-A1c (substance) |
Gnat |
Order Diptera (organism) |
Goes blue (& symptom) |
Goes blue |
Goes blue (& symptom) |
Goes blue |
Goiter, non-toxic NOS |
Simple goiter |
Goitre, non-toxic NOS |
Simple goiter |
Goitre: [nodular NOS] or [adenomatous] |
Adenomatous goiter |
Goitre: [simple] or [retrosternal] or [substernal] or [colloid] or [nodule] |
Colloid goiter |
Goitre: [simple] or [retrosternal] or [substernal] or [colloid] or [nodule] |
Thyroid nodule |
Goitre: [simple] or [retrosternal] or [substernal] or [colloid] or [nodule] |
Simple goiter |
Goitre: [simple] or [retrosternal] or [substernal] or [colloid] or [nodule] |
Substernal goiter |
Golden bowerbird |
Archboldia papuensis subspecies sanfordi (organism) |
Golden bowerbird |
Archboldia papuensis (organism) |
Golden rod pollen |
Goldenrod pollen (substance) |
Golden rod pollen allergen |
Goldenrod pollen (substance) |
Golden whistler |
Pachycephala melanura (organism) |
Golden whistler |
Pachycephala pectoralis (organism) |
Goldfinch |
Genus Carduelis (organism) |
Goldfinch |
Carduelis tristis (organism) |
Goldner operation |
Correction of congenital deformity of hindfoot (procedure) |
Golfer's elbow injection |
Steroid injection into medial epicondyle tendon of humerus (procedure) |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Hypogonadism |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Premature menopause (finding) |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Primary ovarian failure |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Hypogonadism |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
A rare difference of sex development (DSD) characterised by the presence of female external genitalia, ambiguous genitalia or variable defects in virilisation in a 46,XY individual with absent or partial responsiveness to age-appropriate levels of androgens. It comprises two clinical subgroups: complete AIS (CAIS) and partial AIS (PAIS). |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Premature menopause (finding) |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Primary ovarian failure |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Male hypogonadism (disorder) |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
A rare difference of sex development (DSD) characterised by the presence of female external genitalia, ambiguous genitalia or variable defects in virilisation in a 46,XY individual with absent or partial responsiveness to age-appropriate levels of androgens. It comprises two clinical subgroups: complete AIS (CAIS) and partial AIS (PAIS). |
Gonad failure: [other] or [testicular feminisation] or [hypogonadism - male] or [premature menopause] |
Male hypogonadism (disorder) |
Gonadal artery and branches |
Gonadal artery |
Gonadal hormone |
Sex hormone (disposition) |
Gonadal hormone |
Sex hormone (substance) |
Gonadorelin hydrochloride 100mcg powder and solvent for injection solution vial |
Product containing precisely gonadorelin (as gonadorelin hydrochloride) 100 microgram/1 vial powder for conventional release solution for injection (clinical drug) |
Gonadotrophin level borderline |
Gonadotrophin levels above reference range (finding) |
Gonadotrophin level borderline |
Gonadotrophin levels within reference range (finding) |
Gonadotrophin level borderline |
Gonadotrophin levels below reference range (finding) |
Gonadotrophin level borderline |
Gonadotrophin levels below reference range (finding) |
Gonadotrophin level borderline |
Gonadotrophin levels within reference range (finding) |
Gonadotrophin level borderline |
Gonadotrophin levels above reference range (finding) |
Gonadotrophin level borderline high |
Gonadotrophin levels above reference range (finding) |
Gonadotrophin level borderline high |
Gonadotrophin levels within reference range (finding) |
Gonadotrophin level borderline low |
Gonadotrophin levels within reference range (finding) |
Gonadotrophin level borderline low |
Gonadotrophin levels below reference range (finding) |
Gonadotrophin: [levels] or [serum studies] |
Serum gonadotrophin studies (procedure) |
Gonadotrophin: [levels] or [serum studies] |
Serum gonadotrophin studies (procedure) |
Gonadotropin-independent familial sexual precocity |
Familial male limited precocious puberty (FMPP) is a gonadotropin-independent familial form of male-limited precocious puberty, generally presenting between 2-5 years of age as accelerated growth, early development of secondary sexual characteristics and reduced adult height. |
Goniopuncture (& Barkan) |
Goniopuncture |
Goniopuncture |
Goniopuncture without goniotomy |
Goniopuncture |
Goniopuncture |
Goniotomy |
Goniotomy (procedure) |
Goniotomy |
Barkan operation |
Goniotomy |
Goniotomy without goniopuncture |
Goniotomy |
Goniotomy (procedure) |
Goniotomy with goniopuncture |
Goniotomy with goniopuncture |
Goniotomy with goniopuncture |
Barkan operation with goniopuncture (procedure) |
Gonococcal peritonitis |
Fitz-Hugh-Curtis syndrome |
Gonococcal peritonitis |
Gonococcal peritonitis |
Gonococcal periurethral gland abscess |
Gonococcal paraurethral gland abscess |
Gonococcal periurethral gland abscess |
Abscess of urethral gland caused by Neisseria gonorrhoeae |
Gonococcal synovitis &/or tenosynovitis |
Gonococcal tenosynovitis |
Gonococcal synovitis |
Gonococcal tenosynovitis |
Gonococcal synovitis |
Gonococcal synovitis |
Gonococcal synovitis or tenosynovitis |
Gonococcal tenosynovitis |